Target Name: CD14
NCBI ID: G929
Review Report on CD14 Target / Biomarker Content of Review Report on CD14 Target / Biomarker
CD14
Other Name(s): CD14 molecule, transcript variant 1 | Monocyte differentiation antigen CD14 | Monocyte differentiation antigen CD14, urinary form | CD14 molecule, transcript variant 3 | Monocyte differentiation antigen CD14, membrane-bound form | myeloid cell-specific leucine-rich glycoprotein | CD14_HUMAN | soluble monocyte differentiation antigen CD14 | sCD14_(HUMAN) | CD14 variant 3 | CD14 molecule | Myeloid cell-specific leucine-rich glycoprotein | CD14 antigen | CD14 variant 1

CD14: A Potential Drug Target and Biomarker

CD14 is a cell surface glycoprotein that is expressed in various tissues and is involved in various cellular processes. It is a key player in the immune response, being involved in the regulation of inflammation and infection. The CD14 molecule has been identified as a potential drug target and biomarker due to its unique structure and various biological functions. In this article, we will discuss the CD14 molecule, its functions, potential drug targets, and its potential as a biomarker.

Structure and Functions

CD14 is a 14-kDa glycoprotein that consists of a core region with a catalytic domain, a transmembrane region, and an extracellular domain. The catalytic domain is responsible for the molecule's catalytic activity, while the transmembrane region is responsible for the molecule's structural stability. The extracellular domain is involved in the molecule's interactions with other cells and molecules.

CD14 is involved in various cellular processes, including inflammation and infection. It is a key player in the regulation of inflammation, as it has been shown to play a crucial role in the regulation of tissue repair and inflammation following injury or infection. CD14 has also been shown to be involved in the regulation of infection, as it has been shown to interact with various bacterial and viral pathogens.

Potential Drug Targets

CD14 has been identified as a potential drug target due to its unique structure and various biological functions. One of the most promising potential drug targets for CD14 is the inhibition of its catalytic activity. This can be achieved by inhibiting the interaction between CD14 and its catalytic domain, which would prevent the molecule from catalyzing various physiological processes.

Another potential drug target for CD14 is its interaction with certain signaling pathways. For example, CD14 has been shown to interact with the T-cell receptor, which is involved in the regulation of immune responses. This interaction suggests that CD14 may be a target for drugs that are designed to modulate T-cell responses.

Potential Biomarkers

CD14 has also been identified as a potential biomarker due to its unique structure and various biological functions. Its presence and function have been shown to be involved in various physiological processes, including inflammation and infection. This suggests that CD14 may be a useful biomarker for the diagnosis and treatment of various diseases.

Conclusion

CD14 is a cell surface glycoprotein that is involved in various cellular processes, including inflammation and infection. Its unique structure and various biological functions make it a promising candidate as a drug target and biomarker. The inhibition of its catalytic activity and its interaction with certain signaling pathways suggest that CD14 may be a target for drugs that are designed to modulate cellular processes. Further research is needed to confirm its potential as a drug target and biomarker.

Protein Name: CD14 Molecule

Functions: Coreceptor for bacterial lipopolysaccharide (PubMed:1698311, PubMed:23264655). In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:20133493, PubMed:23264655, PubMed:22265692). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:8612135). Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed:23880187)

The "CD14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123